Today is the first day for England’s drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICE faced…

Vertex has pumped up the launch for slow-starting cystic fibrosis med Orkambi--but it took more spending than expected to do it.

Would AstraZeneca really find itself contending with another megamerger offer, this time from Novartis? That’s the speculation on the street, despite signs…

Sanofi finally won FDA approval of its long-awaited GLP-1 diabetes drug Adlyxin. But “finally” is the operative word, and the med will have to scramble with…

It’s a silver-lining quarter for AstraZeneca. Second-quarter sales slid--but not as far as market watchers expected--and new cancer meds, diabetes drugs and…

As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…

With billions in sales under biosimilar threat and facing investor pressure to make M&A moves, Amgen on Wednesday posted revenue and earnings beats for the…

The FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black box. The drugs'…

GlaxoSmithKline CEO Andrew Witty is sitting pretty. For the second straight quarter, his much-maligned growth strategy has come through for the drugmaker,…